Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
- Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders
- Action Plan will provide roadmap and tools to improve approvability, accessibility, acceptability and affordability (4As) of biosimilars
- Sandoz launched initiative to support improved healthcare access, equity and sustainability
Basel, May 31, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …